MitoRx Therapeutics

MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic dysfunction and muscle disease.

Its lead programme is an injectable mitochondria-targeted sulfide donor designed to achieve fat loss without lean mass loss, positioning it as a differentiated alternative to GLP-1 receptor agonists.

Preclinical studies have also demonstrated efficacy in models of Duchenne muscular dystrophy and Alzheimer's disease.